爪真菌症の市場規模、シェア、成長分析：タイプ別、治療法別、地域別 - 産業予測 2025～2032年

爪真菌症の世界市場規模は2023年に53億米ドルと評価され、予測期間（2025～2032年）のCAGRは4.5%で、2024年の55億4,000万米ドルから2032年には78億8,000万米ドルに成長する見通しです。

爪真菌症の診断と治療を中心とする世界の爪真菌症市場は、爪の健康に対する意識の高まりや、加齢、糖尿病、免疫不全などの疾患の有病率の増加により、大きな成長が見込まれています。この市場には、外用および経口の抗真菌薬、ネイルラッカー、レーザー治療や爪の剥離のための高度医療機器など、さまざまな製品が含まれています。主要企業には、製薬会社、医療機器メーカー、ヘルスケアプロバイダーなどが含まれ、市場シェア拡大のために研究開発、製品発売、戦略的提携に取り組んでいます。この市場の主要地域には、北米、欧州、アジア太平洋が含まれ、全身の健康増進を目的とした効果的な治療と革新的なソリューションに対する強い需要が反映されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

爪真菌症市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• 遠位爪下爪真菌症
• ホワイト表面爪真菌症
• 近位爪下爪真菌症
• その他

爪真菌症市場規模：治療法別& CAGR（2025-2032）

• 市場概要
• 経口
• 局所
• その他

爪真菌症市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Bausch Health Companies Inc.（Canada）
• GSK plc（UK）
• Abbott（US）
• Pfizer Inc.（US）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Inc.（India）
• Merck & Co., Inc.（US）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi（France）
• Johnson & Johnson（US）
• Eli Lilly and Company（US）
• Mylan N.V.（US）
• Galderma S.A.（Switzerland）
• Valeant Pharmaceuticals International, Inc.（Canada）
• Sandoz International GmbH（Germany）
• Lupin Limited（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Aurobindo Pharma Limited（India）

結論と推奨事項

Global Onychomycosis Market size was valued at USD 5.3 billion in 2023 and is poised to grow from USD 5.54 billion in 2024 to USD 7.88 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global onychomycosis market, centered on the diagnosis and treatment of nail fungal infections, is poised for significant growth due to rising awareness of nail health and a growing prevalence of conditions such as aging, diabetes, and immune deficiencies. This market encompasses a variety of products including topical and oral antifungal medications, nail lacquers, and advanced medical devices for laser therapy and nail debridement. Key players include pharmaceutical firms, medical device manufacturers, and healthcare providers who are engaging in R&D, product launches, and strategic partnerships to enhance their market share. Major regions for this market include North America, Europe, and Asia Pacific, reflecting a strong demand for effective treatments and innovative solutions aimed at promoting overall well-being.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Market Segmental Analysis

Global Onychomycosis Market is segmented by Type, Treatment and region. Based on Type, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis and others. Based on Treatment, the market is segmented into Oral, Topical and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Onychomycosis Market

The global onychomycosis market is significantly driven by the rising prevalence of various risk factors, including the growing rates of diabetes, an aging population, compromised immune systems, and instances of nail trauma. As these factors elevate the vulnerability to fungal infections, they result in an expanding demographic of patients seeking diagnosis and treatment for onychomycosis. Consequently, this surge in affected individuals underscores the increasing demand for effective therapeutic solutions, thereby propelling market growth. The correlation between these risk factors and the incidence of onychomycosis highlights the urgent need for improved awareness, prevention, and treatment options in the healthcare sector.

Restraints in the Global Onychomycosis Market

One of the significant constraints in the global onychomycosis market is the potential side effects and limitations linked to existing treatment modalities. Although oral antifungal drugs are recognized for their efficacy, they come with risks of systemic side effects, necessitating close monitoring of patients. Furthermore, topical treatments often struggle with effectiveness in addressing severe or deeply entrenched infections. These challenges can impede market expansion and complicate the delivery of safe and effective treatment alternatives for individuals affected by onychomycosis, ultimately affecting patient outcomes and clinician confidence in treatment strategies.

Market Trends of the Global Onychomycosis Market

The global onychomycosis market is witnessing a significant trend towards the development of innovative and convenient treatment solutions, driven by an increasing demand for therapies that prioritize efficacy, shorter treatment durations, and greater patient adherence. Market participants are actively investing in research and development to introduce novel options such as advanced topical formulations, specialized lacquers, and cutting-edge laser therapies. This shift not only enhances treatment effectiveness but also reflects a broader commitment within the industry to address the evolving needs of patients suffering from fungal nail infections, ultimately aiming to improve clinical outcomes and quality of life for affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Onychomycosis Market Size by Type & CAGR (2025-2032)

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• others

Global Onychomycosis Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• others

Global Onychomycosis Market Size & CAGR (2025-2032)

• North America (Type, Treatment)
  • US
  • Canada
• Europe (Type, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International, Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations